Role of urokinase plasminogen activator receptor (CD87) as a prognostic marker in acute myeloid leukemia.

Expression of uPAR (CD87) may play a relevant role in the diagnosis and pathophysiology and prognostic pattern of acute myeloid leukemia. The aims of this study were to find out the prognostic significance of pretreatment detection of CD87 and study the prevalence of CD87 expression and its value as a predictor for survival in AML patients. CD87 expression has been studied on blasts in 110 newly diagnosed AML patients. Immunophenotyping and cytogenetic analysis of these cases were performed. CD87 was positive in 80 (72.7%) cases of patients. The MFI categorized the expression of CD87 into CD87(High) and CD87(Low) expression. Blast cells show that monocytic differentiation has a significantly more CD87(High) expression than CD87(Low) expression. Cytogenetic abnormalities were found in 58.7% of patients with CD87(Low) AML and 41.25% of patients with CD87(High) AML. Cases with CD87(High) expression cells were characterized by a significantly lower survival period especially when co-expressed with CD56, CD34, and/or CD64. There is a negative prognostic influence of the expression of CD87 on the surface of AML blasts, but more tests are necessary to explain the pathophysiological mechanisms behind these findings and to learn about the mechanism that influences the CD87 expression and function.